These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety. Campbell KN; Gesualdo L; Murphy E; Rheault MN; Srivastava T; Tesar V; Komers R; Trachtman H Kidney Med; 2024 Jun; 6(6):100833. PubMed ID: 38831932 [TBL] [Abstract][Full Text] [Related]
8. Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis. Komers R; Diva U; Inrig JK; Loewen A; Trachtman H; Rote WE Kidney Int Rep; 2020 Apr; 5(4):494-502. PubMed ID: 32274453 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET). Komers R; Gipson DS; Nelson P; Adler S; Srivastava T; Derebail VK; Meyers KE; Pergola P; MacNally ME; Hunt JL; Shih A; Trachtman H Kidney Int Rep; 2017 Jul; 2(4):654-664. PubMed ID: 29142983 [TBL] [Abstract][Full Text] [Related]
10. Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease. Kohan DE; Bedard PW; Jenkinson C; Hendry B; Komers R Clin Sci (Lond); 2024 Jun; 138(11):645-662. PubMed ID: 38808486 [TBL] [Abstract][Full Text] [Related]
11. Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: An Open-Label Drug-Drug Interaction Study in Healthy Adults. Chen SC; Cai D; Winnett C; Nguyen M; Verma N; Liu K; Preciado P Clin Pharmacol Drug Dev; 2023 May; 12(5):535-541. PubMed ID: 36852566 [TBL] [Abstract][Full Text] [Related]
13. Renoprotective effects of sparsentan: clinical trial evidence in IgA nephropathy and FSGS. Wang M Nat Rev Nephrol; 2024 Jan; 20(1):6. PubMed ID: 38012264 [No Abstract] [Full Text] [Related]
14. Interventions for focal segmental glomerulosclerosis in adults. Hodson EM; Sinha A; Cooper TE Cochrane Database Syst Rev; 2022 Feb; 2(2):CD003233. PubMed ID: 35224732 [TBL] [Abstract][Full Text] [Related]
15. Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy. Nagasawa H; Ueda S; Suzuki H; Jenkinson C; Fukao Y; Nakayama M; Otsuka T; Okuma T; Clapper W; Liu K; Nguyen M; Komers R; Suzuki Y Nephrol Dial Transplant; 2024 Aug; 39(9):1494-1503. PubMed ID: 38271614 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects. Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536 [TBL] [Abstract][Full Text] [Related]
17. Sparsentan - Another Arrow in the Quiver for Treatment of FSGS? Ingelfinger JR N Engl J Med; 2023 Dec; 389(26):2482-2483. PubMed ID: 37921485 [No Abstract] [Full Text] [Related]
18. Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial. Trachtman H; Diva U; Murphy E; Wang K; Inrig J; Komers R Kidney Int Rep; 2023 Oct; 8(10):2017-2028. PubMed ID: 37850006 [TBL] [Abstract][Full Text] [Related]
19. Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice. Campbell KN; Griffin S; Trachtman H; Geletka R; Wong MG Int J Nephrol Renovasc Dis; 2023; 16():281-291. PubMed ID: 38149041 [TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials. Patel P; Howgate E; Martin P; Carlile DJ; Aarons L; Zhou D Br J Clin Pharmacol; 2018 Jan; 84(1):52-63. PubMed ID: 28833380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]